McElhenny Sheffield Capital Management LLC purchased a new stake in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 131,327 shares of the company’s stock, valued at approximately $13,201,000. iShares U.S. Pharmaceuticals ETF makes up 3.1% of McElhenny Sheffield Capital Management LLC’s holdings, making the stock its 7th biggest position. McElhenny Sheffield Capital Management LLC owned 0.87% of iShares U.S. Pharmaceuticals ETF at the end of the most recent quarter.
A number of other hedge funds have also made changes to their positions in IHE. Balance Wealth Partners LLC purchased a new stake in shares of iShares U.S. Pharmaceuticals ETF in the 3rd quarter worth about $42,000. Russell Investments Group Ltd. grew its stake in iShares U.S. Pharmaceuticals ETF by 148.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 467 shares of the company’s stock valued at $47,000 after acquiring an additional 279 shares during the last quarter. Root Financial Partners LLC acquired a new stake in iShares U.S. Pharmaceuticals ETF in the 3rd quarter valued at about $51,000. Trust Co. of Vermont purchased a new position in iShares U.S. Pharmaceuticals ETF during the 2nd quarter valued at about $60,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in iShares U.S. Pharmaceuticals ETF during the 3rd quarter valued at about $64,000.
iShares U.S. Pharmaceuticals ETF Stock Performance
Shares of IHE opened at $111.03 on Monday. The stock has a market cap of $1.73 billion, a P/E ratio of 33.66 and a beta of 0.48. The company has a 50-day moving average of $103.09 and a two-hundred day moving average of $95.85. iShares U.S. Pharmaceuticals ETF has a 12-month low of $79.82 and a 12-month high of $111.98.
About iShares U.S. Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Featured Articles
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
